1. Latest News
  2. Submit Press Release
  1. PR Home
  2. Latest News
  3. Feeds
  4. Alerts
  5. Submit Free Press Release
  6. Journalist Account
  7. PRNewswire Distribution
NAPSRx Logo

NAPSR News: GlaxoSmithKline's Tanzeum gets FDA approval for type 2 diabetes treatment

GlaxoSmithKline (GSK) has received approval from the US Food and Drug Administration (FDA) for its Tanzeum (albiglutide) subcutaneous injection to improve glycemic control, along with diet and exercise, in adult patients with type 2 diabetes.

 
PRLog - Apr. 16, 2014 - WASHINGTON, D.C. -- GlaxoSmithKline (GSK) has received approval from the US Food and Drug Administration (FDA) for its Tanzeum (albiglutide) subcutaneous injection to improve glycemic control, along with diet and exercise, in adult patients with type 2 diabetes.

The once-weekly treatment of albiglutide, a glucagon-like peptide-1 receptor agonist (GLP-1), is administered using an injector pen supplied with a 5mm 29-gauge thin-walled needle.

GLP-1 is an important incretin hormone that helps reduce blood glucose levels but, in people with type 2 diabetes, its production is often reduced or absent.

GSK senior vice-president and head of Global Cardiovascular, Metabolic and Neurosciences Franchise Vlad Hogenhuis said many type 2 diabetes patients struggle to keep their blood sugar within the recommended levels.

"We are pleased that the approval of Tanzeum provides an effective new weekly GLP-1 treatment option for appropriate patients in the US," Hogenhuis said.

The approval of albiglutide is based on the results of GSK's comprehensive Phase III Harmony program, consisting of eight trials and involving over 5,000 patients, over 2,000 of whom were treated with Tanzeum.

The studies evaluated albiglutide against commonly-used classes of type 2 diabetes treatment, including insulin, metformin, glimepiride and pioglitazone, in patients at different stages of the disease, as well as those with renal impairment.

Following the FDA approval, the company intends launch Tanzeum in the US in the third quarter of 2014.

NOW IS THE TIME TO ENTER INTO THIS WONDERFUL FIELD. With such industry leaders posting gains in profitability, they will need both certified and qualified individuals to sell their product. When industry leaders look for new candidates for entry level positions, they look toward individuals that are industry trained. Reason being that they are looking for people that have the background to sell their product both proficiently and efficiently.

CANDIDATES WHO WANT TO BREAK INTO PHARMACEUTICAL SALES!- Upon successful completion of the training each student will receive the Certification Mark of the CNPR®. The CNPR® represents a level of industry achievement and a demonstrated knowledge of pharmacology, medical terminology, pharmaceutical selling guidelines, physician selling techniques and industry standards. Pharmaceutical sales candidates who have this training will differentiate themselves from other individuals looking for open positions. CNPR® graduates should immediately utilize the NAPSRx® Career Center to apply for pharmaceutical sales positions.

The CNPR is a federally trademarked certification you can earn by demonstrating the necessary knowledge in pharmacology, medical terminology, physiology, and regulations for selling pharmaceuticals. The CNPR examination is dedicated to increasing the professional level of NAPSR members and to developing meaningful and ethical standards fully accepted by both its members and members of the pharmaceutical community.

Individuals that are interested in becoming a Certified National Pharmaceutical Representative(CNPR) can contact the National Association of Pharmaceutical Sales Representatives(NAPSRx) for more information.

Contact
NAPSRx
800-284-1060
***@napsronline.org

--- End ---

Click to Share

Contact Email:
***@napsronline.org
Source:NAPSRx
City/Town:Washington - District of Columbia - United States
Industry:Medical, Science
Tags:napsrx, cnpr, pharmaceutical sales, certification, Training
Shortcut:prlog.org/12310967
Disclaimer:   Issuers of the press releases are solely responsible for the content of their press releases. PRLog can't be held liable for the content posted by others.   Report Abuse

Latest Press Releases By “

More...

Trending News...



  1. SiteMap
  2. Privacy Policy
  3. Terms of Service
  4. Copyright Notice
  5. About
  6. Advertise
Like PRLog?
9K2K1K
Click to Share